Turning the Tide on Cancer
Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.
focusing on cancer indications with the greatest medical need for new treatments
Featured News
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 27, 2020
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
Targeting PLK1, a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1) for the treatment of cancers with the greatest need for new treatment options.
PLK1 is over-expressed in most cancers. Inhibition of PLK1 causes mitotic arrest and subsequent cell death. Emerging data demonstrates that PLK1 is also a key regulator of cellular functions beyond mitosis that are essential for tumor growth.
Targeting a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.